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Abstract The impairment of immunological surveillance
caused by aberrant T cell activation can lead to an inadequate
anti-tumor response. Therefore, deregulation in co-stimulatory
pathway might be associated with cancer susceptibility. Here
we undertook a prospective study to investigate whether gene-
tic variations in gene encoding molecule CD28 and CTLA-4
playing pivotal role in regulating adoptive immune response
can influence susceptibility to prostate cancer. Single nucleo-
tide polymorphisms (SNPs) in CTLA-4 and CD28 genes were
genotyped in 301 prostate cancer (PCa) patients and 301 con-
trols. The distributions of the genotypes and haplotypes in the
CTLA-4/CD28 SNPs were similar in both studied groups.
However, the overrepresentation of carriers of CTLA-
4c.49A>G[A] allele and carriers ofCTLA-4g.319C>T[T] allele
in PCa as compared to controls was observed (p = 0.082 and
p = 0.13, respectively). The risk of disease was higher (OR
1.78) for carriers of both susceptibility alleles as compared to
carriers of protective genotypes (p = 0.03). The CTLA-
4c.49A>G and CTLA-4g.319C>T SNPs might be considered
as low risk susceptibility locus for PCa.
Keywords CTLA-4 .CD28 .Genepolymorphisms .Prostate
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Introduction
Prostate cancer is a common malignancy among men in
Western and Asian Countries and one of the most frequent
causes of mortality and morbidity [1]. The mechanism(s) un-
derlying the development of prostate cancer are still unknown,
but it is postulated that both environmental and genetic factors
play role [2, 3].
Numerous epidemiological studies such as case-control,
cohort and genome-wide association studies have shown the
role of low-risk genetic variation in susceptibility to PCa [4].
Genome-wide association studies [5–9] have identified 77
susceptibility loci for prostate cancer that explain approxi-
mately 30% of the familial risk of prostate cancer. To date,
the number of genes identified as predisposing to PCa is lim-
ited and includes, among others, genes involved in the DNA
damage response pathway, in cell-cycle regulation, signal
transductions, angiogenesis and the most interesting for us –
immune response against tumor.
One of the most important mechanisms in cancer develop-
ment and progression is the impairment of immunological
surveillance caused by aberrant T cell activation, which leads
to an inadequate anti-tumor response [10]. The level of T cell
activation depends on the balance between co-stimulatory and
co-inhibitory signals delivered by co-signaling molecules.
CD28, constitutively expressed on the majority of T cells, is
the primary T-cell co-stimulatory molecule which enhances T-
cell activation and proliferation [11]. CTLA-4 is a down-
regulatory molecule only minimally expressed on resting T
cells, and it is transiently up-regulated after stimulation [11].
CD28 and CTLA-4 are structurally similar and they share
30% of sequence homology [12]. Both CD28 and CTLA-4
bind to the ligands: CD80 and CD86 via MYPPY motif, but
due to the binding of one CTLA-4 homodimer to two CD80
molecules the avidity of this molecule is higher than for CD28
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[13]. As was shown on animal model the absence of CTLA-4
signaling causes constitutive activation of protein tyrosine ki-
nases: FYN, LCK and ZAP-70 [14]. CTLA-4 has YVKM
motif which binds the SHP2 domain of tyrosine phosphatase
SHP2, what results in defosforylation of CD3ζ chain and re-
ducing the signaling potential of T-cell receptor. Furthermore,
the phosphatase PP2A binds to lysine rich motif on the cyto-
plasmic tail of CTLA-4, what results in decreased downstream
AKT phosphorylation [15].
The abnormal CTLA-4 antigen functioning may be one of
the mechanisms responsible for tumor development. Blocking
CTLA-4 antigen on the surface of T cells promotes the regres-
sion of experimentally induced tumors in mice, suggesting the
involvement of this receptor in the pathogenesis of neoplasms
[16, 17]. Encouraging results obtained in animal models were
the basis for the application of a CTLA-4 blockade in the
treatment of different cancers in humans [18]. The exact
mechanism of antitumor response caused by blocking
CTLA-4 is not well established, but it is postulated that it
may be a combination of several effects. CTLA-4 blocking
might act by lowering the threshold needed for T cell activa-
tion, by reduction in the number of Tregs and also by reducing
the release of suppressive molecules such as: IL-10, IL-35,
TGF-β as well as idoleamine 2,3 dioxygenase (IDO). These
mechanisms enhance an antitumor immunity by promoting T-
cell activation and cytotixic T lymphocyte proliferation
(reviewed in [19]).
The prostate cancer was one of the first cancers where this
innovative approach was examined. Currently, in clinical trials,
two IgG monoclonal antibodies, ipi l imumab and
tremelimumab [20], are being tested mainly as part of complex
immunomodulatory maneuvers. However, anti-CTLA-4 treat-
ment may cause immune related adverse effects (irAE), such
as: skin lesions (rush, pruritus and vitiligo), colitis, and less
frequently hepatitis, hypophysitis, thyroiditis and some rare
events: sarcoidosis, uveitis, polymyalgia. On the other hand,
the occurrence of irAEs is positively related to oncologic re-
sponse. It was shown that 60% of patients treated with CTLA-
4 blocking presenting with irAEs experienced clinical response
(partial or complete) or at least cancer stabilization [21].
Immune response against prostate tumor is evidenced by
intratumoral leukocyte infiltration and inflammatory pathway
activation [22, 23], which suggests that host immune system
can mount a natural antitumor response that employs both
initiate and adoptive branches. Therefore, we undertook a
prospective study to investigate, whether genetic variations
in genes encoding molecule CD28 and CTLA-4 playing piv-
otal role in regulating adoptive immune response, can influ-
ence susceptibility to prostate cancer. We have focused our
attention on single nucleotide polymorphisms (SNPs) in the
CTLA-4 gene: CTLA-4c.49A>G (rs231775), CTLA-
4g.319C>T (rs5742909), CTLA-4g.*6230G>A (CT60)
(rs3087243), CTLA-4g.*10223G>T (Jo31) (rs11571302)
and CD28 gene: CD28c.17+3T>C (rs3116496), CD28c.-
1042G>A (rs3181098).
To the best of our knowledge it is the first study on this
subject.
Materials and Methods
We prospectively recruited 301 prostate tumor patients
treated at the Department of Urology and Oncologic
Urology, Wroclaw Medical Univers i ty, between
March 2010 and March 2014. All patients were diagnosed
with prostate cancer on prostate biopsy before and were
admitted for curative treatment (prostatectomy or radio-
therapy) to the ward. After giving written informed consent
all subjects were enrolled to the study before treatment
initiation. The control group consisted of 301 healthy
men originating from the same geographical area as the
patients, recruited from the blood bank in Wroclaw or from
employees of the Institute of Immunology and Experimental
Therapy.
The study was approved by the local ethics committee, and
all participants gave written informed consent.
Genotyping
The SNPs g.319C>T in the promoter region, c.49A>G in exon
1, and CT60 in the 3′ untranslated region (UTR) of the CTLA-
4 gene were examined by polymerase chain reaction restric-
tion fragment length polymorphism (PCR-RFLP) using TruI,
BseXI, and TailI enzymes (Fermentas, Burlington Ontario,
Canada), as described previously [24].
The Jo31, CD28c.17+3 T>C and CD28c.-1042G>A SNPs
were genotyped using the TaqMan®SNP Genotyping Assays:
C__2415786_10, C__25922478_10_and C__27467172_10,
respectively (Applied Biosystems, Foster City, USA).
For quality controls, we performed 10% re-typing with a
double-blind check. Additionally, we conducted retyping
using the following method: the SNPs g.319C>T, c.49A>G,
and CT60 in the CTLA-4 gene were typed using
TaqMan®SNP Genotyping Assays, while the Jo31 and
CD28c.17+3T>C SNPs were identified using PCR followed
by single-nucleotide primer-extension methods as described
in Suwalska et al. [12].
Statistical Analyses
Hardy-Weinberg equilibrium (HWE) was evaluated indepen-
dently for the patients and the controls by comparing the ob-
served and expected frequencies of genotypes using χ2 analysis.
The χ2 test was used to compare categorical data between
groups. Odds ratios (OR) and 95% confidence intervals (95%
CI) were calculated using the binary logistic regression model.
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The haplotype frequencies for pairs of alleles were determined
using the SHEsis program [25]. Haplotypes with frequencies
lower than 0.03 were not included in further analyses. The sig-
nificance of two genetic factors affecting the risk of PCa was
determined with the use of Svejgaard and Ryder method [26].
Differences were considered statistically significant if p < 0.05.
Results
Each polymorphism in the CTLA-4 and CD28 genes was in
HWE in both the cases and the controls.
CTLA-4 and CD28 Gene Polymorphisms
and Susceptibility to the Development of Prostate Cancer
The distributions of the alleles and genotypes for all tested
polymorphisms are presented in Table 1. The analysis re-
vealed that the frequency of alleles, and genotypes for the
investigated polymorphisms in the CTLA-4 and CD28 genes
did not significantly differ between the PCa patients and the
controls. However, we observed an overrepresentation of in-
dividuals possessing theCTLA-4c.49A>G[A] allele compared
to the CTLA-4c.49A>G[GG] genotype among the PCa
patients (0.86 vs 0.80, p = 0.082, OR 1.46, 95% CI: 0.95–
2.25). There was also not significant prevalence of the carriers
of [T] allele in CTLA-4g.319C>T SNP in PCa patients (0.26
vs 0.20, p = 0.13, OR 1.35, 95% CI: 0.92–1.97).
To assess the significance of two genetic factors associated
with PCa risk the Svejgaard and Ryder [26] method was
employed. The following factors were considered: factor A
– possessing of [A] allele at CTLA-4c.49A>G (genotype
[AA] and [AG]); factor B - possessing of [T] allele at CTLA-
4g.319C>T (genotype [CT] and [TT]). The results of that
analysis are presented in Table 2. The frequency of the carriers
of susceptibility alleles for both SNPs (factor A and factor B)
was significantly higher in the PCa patients as compared to the
individuals lacking factor A and B (test [8] Table 2) and
possessing of both factors A and B increased the risk of dis-
ease 1.78 fold (OR 1.78, 95% CI: 1.06–3.01, p = 0.03). In
addition, we observed the tendency to higher risk of PCa in the
individuals possessing factor A and lacking factor B as com-
pared to the group of factors A and B negative persons (test
[4]) (OR 1.51, 95% CI: 0.96–2.37, p = 0.07).
Since CD28 and CTLA-4 genes are located next to each
other on the same chromosome we have performed haplotype
estimation analysis (Table 3). There were no differences in
haplotype distribution between the PCa patients and the con-
trols (Global p = 0.85). The most common haplotype for both
groups was the haplotype consisted of wild alleles CTLA-
4c.49A>G[G]/CTLA-4g.319C>T[C]/CT60[G]/Jo31[G]/
CD28c.17+3T>C[T]/CD28c.-1042G>A[G] (0.26 for PCa and
0.28 for controls).
Discussion
PCa is complex malignancy associated with multiple factors:
age, gene and environment. Host immune system can mount a
natural antitumor response that employs both initiate and
adoptive branches, what was evidenced by intratumoral leu-
kocyte infiltration and inflammatory pathway activation in
prostate tumors [22, 23].
The polymorphisms in co-stimulatory molecule genes
were shown to be genetic susceptibility factors for sev-
eral human cancers [27–32], therefore we hypothesized that
they might influence susceptibility to prostate cancer in Polish
population.
Firstly, CTLA-4 genetic variability was investigated in dif-
ferent ethnic groups in autoimmune diseases, but the results of
the study were conflicting. Recent series of meta-analysis
pointed out, that CTLA-4 locus is rather general autoimmune
than disease-specific genetic risk factor, especially the exon 1
and 3’UTR located markers, while their association with dis-
eases susceptibility depends on the ethnicity. For example, it
was shown that CTLA-4c.49A>G[G] and CT60[G] alleles are
risk factors, especially in Caucasians or Asians, for: autoim-
mune thyroid diseases [33], autoimmune adrenal insufficiency
[34], type 1 diabetes [35], rheumatoid arthritis [36] and sys-
temic lupus erythematosus [37, 38]. The only association be-
tweenCTLA-4g.319C>Tand autoimmune disease susceptibil-
ity was observed for SLE in Asians [38].
Nowadays it is well established that polymorphisms in
CTLA-4 gene also confer susceptibility to cancers. In the
present work we found the not statistically significant pre-
dominance of carriers of CTLA-4c.49A>G[A] allele in PCa
patients as compared to controls. The A>G transition at posi-
tion 49 in exon 1 (CTLA-4c.49A>G) causes a Thr/Ala substi-
tution in the leader peptide and affects the inhibitory function
of the CTLA-4 [39–41], therefore, might play a role in antitu-
mor immunity. The presence of [AA] genotype was shown to
be associated with significantly lower activation and prolifera-
tion of T lymphocytes than [GG] genotype. The protein
product coded by CTLA-4c.49A>G[AA] genotype CTLA-
417Thr had higher capacity to bind B7.1 and a stronger inhi-
bitory effect on T-cell activation compared with CTLA-417Ala
[41]. It has also been postulated that the CTLA-4c.49A>G
polymorphism in the leader sequence may influence rates of
endocytosis or surface trafficking [39], the glycosylation of
CTLA-4, and intracellular/surface partitioning, and in that
way alter inhibitory function of that molecule [40]. The role
of the CTLA-4c.49A>G[A] allele as a risk factor for
cancer development was shown in many types of cancers,
such as esophageal cancer, gastric cardia cancer [41], non-
Hodgkin’s lymphoma [28], breast cancer [27, 41], and renal
cancer [42].
Interestingly, the opposite results for this SNP were shown
for mucosa-associated lymphoid tissue lymphoma [43] and
CD28/CTLA-4 gene polymorphisms and prostate cancer risk
multiple myeloma [44], while no associations with cancer risk
were observed for colorectal cancer [45], chronic lymphocytic
leukemia [30], cervical squamous cell carcinoma [29], malig-
nant melanoma [46], or non-malignant melanoma [47].
Resuming, in our study we observed the trend for overrep-
resentation of carriers of [A] allele among PCa patients.
Although in the present literature this is the first study on an
association between the CTLA-4 gene polymorphisms and
Table 1 Distribution of alleles and genotypes of the following SNPs: CTLA-4c.49A>G, CTLA-4g.319C>T, CTLA-4g.*6230G>A (CT60), CTLA-
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prostate cancer, but CTLA-4c.49A>G[A] allele is established as
a risk factor for several types of cancers, for example: cervical
cancer [48], lung cancer and breast cancer in European [49].
Similarly for the promoter CTLA-4g.319C>T polymor-
phism we have noticed the prevalence of carriers of [T] allele
in PCa patients as compared to healthy man. The CTLA-
4g.319C>T SNP influences promoter activity and the expres-
sions of both CTLA-4 mRNA in unstimulated cells and cell-
surface CTLA-4 on activated cells [50, 51]. Therefore the [T]
allele may contribute to the upregulation of the expression of
the down-regulatory CTLA-4 molecule, inhibition of the ac-
tivation of T lymphocytes, and eventually limitation of the
potency of antitumor immunity, and in that way susceptibility
to cancer. Previously we have shown an association between
this promoter polymorphism and B-cell chronic lymphocytic
leukemia [30]. Moreover, it was found by us and others that
the same allele confers susceptibility to female-related can-
cers: sporadic breast cancer [31, 48], and cervical cancer
[29, 32] as well as non-small cell lung cancer in women
[24]. In contrast to our results CTLA-4g.319C>T polymor-
phism was not associated with lung cancer (without stratifica-
tion by gender) [41] or other cancers, such as colon cancer
[42], colorectal cancer [52] or multiple myeloma [44]. The
meta-analysis performed by Zhang et al. [49] indicated this
polymorphism as related to cancer risk in the Europeans.
Taking together, the individuals possessing two suscepti-
bility alleles for both: CTLA-4c.49A>G and CTLA-
4g.319C>T SNPs have higher risk of development PCa as
compared to individuals with two protective genotypes.
The functional role of CTLA-4g.*6230G>A (CT60) poly-
morphism has been shown by Ueada et al. [53]. This SNP
influences the ratio between mRNA for full length and soluble
form of CTLA-4. The results from our previous study indicat-
ed that this SNP, together with Jo31, is associated with varia-
tions in the levels of membrane and cytoplasmic CTLA-4 in
CD4+ T lymphocytes in multiple sclerosis patients [54], thus
enhancing the activity of T-cells.
In the present study we have not found the association
between CT60 and Jo31 SNPs, which are in strong linkage
disequilibrium, with susceptibility to prostate cancer.
Table 3 Distribution of haplotypes for following SNPs: CTLA-
4c.49A>G, CTLA-4g.319C>T, CTLA-4g.*6230G>A (CT60), CTLA-
4g.*10223G>T (Jo31), CD28c.17+3T>C and CD28c.-1042G>A in
prostate cancer patients compared with controls
haplotype* Case (freq) Control (freq) p OR [95%CI]
N = 301 N = 301
A C AT TA 111.04 ( 0.18) 109.41 (0.18) 0.81 1.04 [0.77–1.40]
A C AT T G 88.38 (0.15) 87.02 (0.15) 0.83 1.04 [0.75–1.44]
A C G G T G 33.58 (0.06) 30.15 (0.05) 0.62 1.14 [0.69–1.89]
AT G G C G 46.67 (0.08) 44.81 (0.07) 0.79 1.06 [0.69–1.63]
AT G G T G 21.18 (0.04) 14.29 (0.02) 0.22 1.53 [0.77–3.02]
G C G G TA 52.47 (0.09) 58.53 (0.10) 0.60 0.90 [0.61–1.33]
G C G G T G 154.59 (0.26) 170.73 (0.28) 0.35 0.88 [0.68–1.15]
Global Chi2 = 2.67, df = 6 (frequency < 0.03 in both control & case has
been dropped)
Pearson’s p value is 0.85
*The order of SNPs in estimated analysis of haplotypes frequency:
CTLA-4c.49A>G, CTLA-4g.319C>T, CTLA-4g.*6230G>A (CT60),
CTLA-4g.*10223G>T (Jo31), CD28c.17+3T>C and CD28c.-1042G>A
Table 2 Analysis of the associations between two genetic factors carriers ofCTLA-4c.49A>G[A] allele andCTLA-4 g.319C>T[T] allele with prostate
cancer risk using Svejgaard and Ryder method [26]
Basic data Factor A: CTLA-4c.49A>G (rs231775) [AA] + [AG]





A+, B+ 75 62
A+, B- 183 179
A-, B+ 3 0
A-, B- 40 59
Test OR p 95%CI Comparison Individual association
[1] A 1.46 0.08 0.95–2.25
[2] B 1.35 0.13 0.92–1.97
[3] ++ vs − + NA 0.33* NA A in B-positive A association
[4] + − vs -- 1.51 0.07 0.96–2.37 A in B-negative
[5] ++ vs + − 1.18 0.40 0.80–1.76 B in A-positive B association
[6] − + vs -- NA 0.14* NA B in A-negative
[7] + − vs − + NA 0.26* NA Differences between A and B association
[8] ++ vs -- 1.78 0.03 1.06–3.01 Combined association
*- p-value after Yate’s correction (when at least one n ≤ 5)
CD28/CTLA-4 gene polymorphisms and prostate cancer risk
Interestingly, the association of the both SNPs with another
urinary cancer – clear cell renal cell cancer was found by our
group [55]. An increasing number of studies have been devot-
ed to the association between the CT60 and Jo31 SNPs and
cancers. The latest meta-analysis indicated that CT60 SNP is
associated with the risk of breast cancer and cervical cancer
especially in Asian population [56].
The functional roles of CD28c.17+3 T>C and CD28c.-
1042G>A have not been clearly established. It is known that
the CD28c.17+3T>C polymorphic site is situated within a
region where a splice receptor site for CD28 is present, while
CD28c.-1042G>A has been shown to be associated with re-
duced metastases-free survival in melanoma patients [46]. No
association was found in the present study in the univariate
analysis between CD28 gene polymorphisms (c.17+3T>C
and c.-1042G>A) and susceptibility to PCa.
A limitation of this study is the relatively small group of
patients, but this group is genetically homogenous, which was
reflected in virtually identical frequencies of H-Y polymor-
phisms in different regions of Poland [57]. Since this is the
first report on the association of the CD28/CTLA-4 gene re-
gion and prostate cancer risk, additional studies will be impor-
tant to confirm and extend our results.
In conclusion: The functional polymorphisms in CTLA-4
gene, which influence the surface protein level, might be con-
sidered as potential low risk factors for PCa development, but
keeping in view the correction for multiple hypothesis testing,
our results should be treated with caution and require further
studies on a larger group of patients.
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